scout
|Articles|September 1, 2006

Oncology NEWS International

  • Oncology NEWS International Vol 15 No 9
  • Volume 15
  • Issue 9

Phase I/II Trial of AGS-003

Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.

DURHAM, North Carolina—Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME